|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **YEAR** | **FIRST AUTHOR** | **CKI** | **CK2** | **CK3** | **CK4** | **CK5** | **CK6** | **CK7** | **CK8** | **CK9** | **CK10** | **CK11** | **CK12** | **CK13** | **CK14** | **QUALITY** | **COMMENTS** |
| 2013 | Afonso L.A | Y | Y | NR | Y | N | N | N | Y | Y | N | Y | NA | NA | Y | POOR | male population |
| 2017 | Amaral JLA | Y | Y | NR | Y | N | N | N | CD | Y | N | N | NA | NA | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2012 | Araujo A.C.L | Y | Y | NR | Y | N | Y | Y | N | Y | N | Y | NA | Y | Y | FAIR | insufficient data on prevalence of HPV types in normal cytology results |
| 2014 | Araujo M.P | Y | Y | NR | Y | N | N | N | CD | CD | NR | Y | NA | NA | N | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2017 | Ayres A.R.G | Y | Y | Y | Y | N | N | N | CD | CD | NR | N | NA | NA | Y | POOR | normal cytology data not available |
| 2018 | Badial R.M | Y | Y | NR | Y | N | Y | Y | CD | Y | N | Y | NA | NR | Y | GOOD |  |
| 2009 | Baldez da Silva M.F.P.T | Y | N | NR | Y | N | N | CD | CD | CD | NR | CD | NA | NR | N | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2011 | Baldin-Dal Pogetto M.R | Y | Y | Y | Y | N | CD | CD | CD | CD | NR | Y | NA | NR | N | POOR | normal cytology data not available |
| 2017 | Batista J.E | Y | CD | Y | Y | Y | N | N | NA | Y | N | Y | NA | NR | Y | FAIR | insufficient data on prevalence of HPV types in normal cytology results |
| 2009 | Brandao V. da C.R.A.B | Y | Y | NR | N | N | N | N | CD | Y | N | Y | NA | NR | Y | GOOD |  |
| 2002 | Brito E.B | N | CD | NR | Y | N | N | N | N | CD | NR | CD | NA | NR | Y | POOR | no crossectional or cohort study. no clear objective of study |
| 2005 | Brito E.B | Y | Y | NR | N | N | N | N | N | CD | NR | Y | NA | NR | N | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2014 | Bruno A | Y | Y | NR | Y | Y | Y | Y | Y | Y | NR | Y | NA | NR | Y | GOOD |  |
| 2015 | Cambou M.C | Y | Y | NR | Y | N | N | N | CD | Y | N | NR | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2006 | Carestiato F.N | Y | Y | NR | N | N | N | N | N | Y | N | CD | NA | NR | Y | POOR | male population |
| 2003 | Carvalho M.O.O | Y | Y | NR | N | N | N | N | N | Y | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2005 | Carvalho M.O.O | Y | Y | NR | N | N | N | N | N | Y | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2011 | Castro M.M | Y | N | NR | N | N | CD | CD | CD | CD | CD | CD | NA | NR | N | FAIR | molecular biology study |
| 1994 | Cavalcanti SMB | Y | Y | NR | N | N | CD | CD | CD | Y | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2007 | Cerquiera D.M | Y | Y | NR | Y | N | N | N | N | Y | NR | Y | NA | NR | Y | GOOD |  |
| 2013 | Chevarie-Davis M | Y | Y | NR | Y | N | NR | NR | NR | NR | Y | NR | NA | N | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2011 | Correa C.M | Y | Y | NR | N | Y | N | N | NR | Y | N | Y | NA | NR | Y | POOR | normal cytology data not available |
| 2013 | Coser J | Y | Y | NR | Y | N | N | N | CD | CD | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2017 | Costa-Lira E | Y | Y | NR | Y | N | N | N | N | Y | N | Y | NA | NR | Y | GOOD |  |
| 2012 | Da Silva C.M | Y | Y | NR | Y | N | N | N | N | Y | N | Y | NA | NR | Y | GOOD |  |
| 2012 | De Abreu A.L.P | Y | Y | NR | N | N | N | N | N | Y | N | Y | NA | NR | Y | FAIR | sample size <10 participants |
| 2014 | De Almeida F.G | Y | N | NR | N | NR | N | N | NR | CD | CD | Y | NA | NR | Y | POOR | normal cytology data not available |
| 2014 | De Araujo Resende.L.S | Y | CD | NR | N | NR | CD | CD | CD | Y | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2011 | De Mattos A.T | Y | Y | NR | N | NR | N | N | N | NR | N | Y | NA | NR | N | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2008 | De Medeiros Fernandes T.A.A | Y | Y | NR | Y | NR | N | N | N | NR | N | Y | NA | NR | Y | FAIR | limited number of HPV type specific PCR results |
| 2013 | De Oliveira G.R |  |  |  |  |  |  |  |  |  |  |  |  |  |  | POOR | Non- English |
| 2017 | De Oliveira G.R | Y | N | NR | N | NR | CD | CD | CD | N | N | Y | NA | NR | N | POOR | molecular biology study |
| 2007 | De Paula F.D.F | Y | N | NR | N | NR | N | N | N | Y | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2004 | Derchain S.F.M | Y | N | NR | CD | NR | N | N | N | N | N | N | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2017 | Duarte D. V | Y | N | NR | N | NR | N | N | N | N | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2009 | Fernandes J.V | Y | Y | NR | Y | NR | N | N | N | N | N | Y | NA | NR | Y | FAIR | limited number of HPV type specific PCR results |
| 2013 | Fernandes J.V | Y | Y | NR | Y | NR | N | N | N | Y | N | Y | NA | NR | N | FAIR | limited number of HPV type specific PCR results |
| 2013 | Figueiredo A.R.R | Y | Y | Y | Y | NR | N | N | N | N | N | Y | NA | NR | N | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2015 | Freire M.P.A | Y | Y | NR | Y | NR | N | N | N | Y | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2017 | Goncalves A.R.R | Y | Y | Y | Y | NR | N | N | N | N | N | Y | NA | NR | Y | POOR | normal cytology data not available |
| 2002 | Levi J. E | Y | Y | NR | N | NR | N | N | N | Y | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2016 | Martins T.R | Y | Y | NR | Y | NR | N | N | N | Y | N | Y | NA | NR | Y | GOOD |  |
| 2012 | Miranda P.M | Y | N | NR | Y | NR | N | N | N | Y | N | Y | NA | NR | Y | GOOD |  |
| 2018 | Nascimento M.D.S.B | Y | Y | NR | Y | Y | N | N | N | Y | N | Y | NA | NR | Y | GOOD |  |
| 2006 | Oliveira L.H.S | Y | Y | NR | N | NR | N | N | N | CD | CD | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2011 | Oliveira-Silva M | Y | Y | NR | Y | NR | N | N | N | Y | N | Y | NA | NR | Y | GOOD |  |
| 2007 | Pereira C.R.N | Y | Y | NR | Y | NR | Y | Y | N | Y | N | Y | N | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2004 | Queiroz C. | Y | Y | NR | N | NR | N | N | N | Y | N | Y | NA | NR | N | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2008 | Rama C.H | Y | N | NR | N | NR | N | N | N | N | N | Y | NA | NR | N | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2014 | Rebelo C.P.A | Y | Y | NR | N | NR | N | N | N | Y | N | Y | NA | NR | Y | POOR | molecular biology study |
| 2013 | Rocha D.A.P | Y | N | NR | Y | Y | N | N | N | N | N | Y | NA | NR | Y | POOR | insufficient data on prevalence of HPV types in normal cytology results |
| 2003 | Rosseau M.C | Y | Y | NR | Y | NR | Y | Y | N | Y | Y | Y | N | NR | Y | FAIR | normal cytology data not available |
| 2015 | Salcedo M.M.B.P | Y | Y | NR | Y | NR | Y | N | N | Y | N | Y | N | NR | Y | POOR | normal cytology data not available |
| 2018 | Serra I.G.S.S | Y | Y | Y | Y | Y | N | N | N | Y | N | Y | NA | NR | Y | GOOD |  |
| 2018 | Teixeira M.F | Y | Y | Y | Y | Y | N | N | N | Y | N | Y | NA | NR | Y | FAIR | limited number of HPV type specific PCR results |
| 2014 | Vasconcellos de Aguiar S.R | Y | Y | NR | Y | Y | N | N | N | Y | N | Y | NA | NR | Y | POOR | normal cytology data not available |
| 2015 | Veira R.C | Y | Y | NR | Y | NR | N | N | N | N | N | Y | NA | NR | N | POOR | normal cytology data not available |

Rater #1 initials:

Rater #2 initials:

Cross-Sectional Studies (https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort).

CK 1. Was the research question or objective in this paper clearly stated?

CK 2. Was the study population clearly specified and defined?

CK 3. Was the participation rate of eligible persons at least 50%?

CK 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?

 CK 5. Was a sample size justification, power description, or variance and effect estimates provided?

 CK 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?

CK 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?

 CK 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?

CK 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

CK 10. Was the exposure(s) assessed more than once over time?

 CK 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

CK 12. Were the outcome assessors blinded to the exposure status of participants?

 CK 13. Was loss to follow-up after baseline 20% or less?

CK 14. Were key potential confounding variablesmeasured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?